Analyst Ranking
Bottom 20%
#4021 out of 5017 analysts
Average Return
-0.29%
Win Rate
37%16 out of 43
Risk vs Reward
Poor
Good

Uy Ear's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Arcutis Biotherapeutics IncARQT
+306.12%$3.43$13.93
2024-01-02 -
2024-12-31
Strong Buy
Arcutis Biotherapeutics IncARQT
+272.38%$3.91$14.56
2024-01-02 -
2025-01-02
Strong Buy
Cabaletta Bio IncCABA
+131.36%$8.10$18.74
2023-03-16 -
2024-03-15
Strong Buy
Arcutis Biotherapeutics IncARQT
+47.19%$9.24$13.60
2024-05-14 -
2025-05-14
Strong Buy
Evolus IncEOLS
+41.71%$8.75$12.40
2023-06-06 -
2024-06-06
Strong Buy

Uy Ear Analyst Color

Get additional color on Uy Ear's coverage of popular stocks

Uy Ear's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Acadia Pharmaceuticals IncACAD
14Hold$24.00-2.72%Maintains
a month ago
Mbx Biosciences IncMBX
1Buy$38.00+249.59%Initiates Coverage On
a month ago
Sarepta Therapeutics IncSRPT
7Hold$14.00-19.86%Downgrades
2 months ago
Tectonic Therapeutic IncTECX
6Buy$85.00+412.36%Maintains
4 months ago
Arcutis Biotherapeutics IncARQT
13Buy$21.00+24.04%Maintains
7 months ago
Uniqure NvQURE
4Hold$20.00+34.82%Maintains
9 months ago
Relmada Therapeutics IncRLMD
1Hold$1.00-40.12%Downgrades
9 months ago
Alkermes PLCALKS
5Buy$40.00+50.83%Maintains
10 months ago
Sage Therapeutics IncSAGE
2Hold$16.00N/AMaintains
a year ago
Cartesian Therapeutics IncRNAC
3Strong Buy$40.00N/AInitiates Coverage On
a year ago
Evolus IncEOLS
3Strong Buy$23.00N/AMaintains
2 years ago
Neurocrine Biosciences IncNBIX
9Hold$140.00N/AMaintains
2 years ago
Revance Therapeutics IncRVNC
1Strong Buy$16.00N/AMaintains
2 years ago
Johnson & JohnsonJNJ
1Strong Buy$40.00N/AMaintains
2 years ago
Satsuma Pharmaceuticals IncSTSA
1Hold$2.00N/AReiterates
2 years ago
Cabaletta Bio IncCABA
1Strong Buy$10.00N/AReiterates
2 years ago
Ocugen IncOCGN
2Strong Buy$3.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.